Lin−/HLA-DR+ CBDC: Frequency, Enrichment, and Recovery in the Course of Isolation
| . | WBC ×107 . | % WBC Recovery . | % HLA-DR+ . | % Lin−/ HLA-DR+ . | CBDC ×105 . | Fold CBDC Enrichment . | % CBDC Recovery . |
|---|---|---|---|---|---|---|---|
| CB | 60.3 ± 33.5 | 100 | 11.5 ± 2.1 | <0.1% | |||
| (13.1-130.4) | (7.7-14.8) | (0.01-0.05) | |||||
| n = 20 | n = 7 | n = 7 | |||||
| CBMC | 12.1 ± 8.1 | 18.5 ± 6.7 | 36.5 ± 8.3 | 0.3 ± 0.1 | 3.4 ± 2.4 | 1 | 100 |
| (0.7-38.0) | (8.6-33.5) | (25.5-55.0) | (0.1-0.6) | (1.0-9.1) | |||
| n = 36 | n = 17 | n = 15 | n = 15 | n = 15 | |||
| SRBC− | 5.2 ± 3.4 | 6.2 ± 2.4 | 63.4 ± 10.2 | 0.5 ± 0.2 | 1.4 ± 0.8 | 2.0 ± 0.7 | 59.5 ± 20.4 |
| (0.4-20.5) | (2.3-9.7) | (48.8-82.1) | (0.2-0.8) | (0.3-3.0) | (0.7-3.1) | (26.9-84.4) | |
| n = 66 | n = 11 | n = 9 | n = 9 | n = 9 | n = 8 | n = 8 | |
| Lin−-enriched | 0.04 ± 0.04 | 0.03 ± 0.01 | 42.4 ± 21.8 | 27.1 ± 18.2 | 0.8 ± 0.7 | 110.4 ± 61.2 | 34.6 ± 21.4 |
| (0.001-0.17) | (0.01-0.04) | (12.8-89.3) | (4.6-70.9) | (0.03-3.0) | (43.0-253.3) | (8.8-71.6) | |
| n = 40 | n = 7 | n = 37 | n = 37 | n = 35 | n = 9 | n = 8 |
| . | WBC ×107 . | % WBC Recovery . | % HLA-DR+ . | % Lin−/ HLA-DR+ . | CBDC ×105 . | Fold CBDC Enrichment . | % CBDC Recovery . |
|---|---|---|---|---|---|---|---|
| CB | 60.3 ± 33.5 | 100 | 11.5 ± 2.1 | <0.1% | |||
| (13.1-130.4) | (7.7-14.8) | (0.01-0.05) | |||||
| n = 20 | n = 7 | n = 7 | |||||
| CBMC | 12.1 ± 8.1 | 18.5 ± 6.7 | 36.5 ± 8.3 | 0.3 ± 0.1 | 3.4 ± 2.4 | 1 | 100 |
| (0.7-38.0) | (8.6-33.5) | (25.5-55.0) | (0.1-0.6) | (1.0-9.1) | |||
| n = 36 | n = 17 | n = 15 | n = 15 | n = 15 | |||
| SRBC− | 5.2 ± 3.4 | 6.2 ± 2.4 | 63.4 ± 10.2 | 0.5 ± 0.2 | 1.4 ± 0.8 | 2.0 ± 0.7 | 59.5 ± 20.4 |
| (0.4-20.5) | (2.3-9.7) | (48.8-82.1) | (0.2-0.8) | (0.3-3.0) | (0.7-3.1) | (26.9-84.4) | |
| n = 66 | n = 11 | n = 9 | n = 9 | n = 9 | n = 8 | n = 8 | |
| Lin−-enriched | 0.04 ± 0.04 | 0.03 ± 0.01 | 42.4 ± 21.8 | 27.1 ± 18.2 | 0.8 ± 0.7 | 110.4 ± 61.2 | 34.6 ± 21.4 |
| (0.001-0.17) | (0.01-0.04) | (12.8-89.3) | (4.6-70.9) | (0.03-3.0) | (43.0-253.3) | (8.8-71.6) | |
| n = 40 | n = 7 | n = 37 | n = 37 | n = 35 | n = 9 | n = 8 |
In the course of CBDC isolation, CB nucleated cells, CBMC, SRBC− cells, and lin−-enriched cells were double labeled with lin-specific (CD3, CD11b, CD14, CD16, CD19, CD34, CD56, and glycophorin A) MoAb and anti–HLA-DR and analyzed by flow cytometry. WBC counts were determined as described in Materials and Methods. Results are shown as mean ± SD of the number of experiments indicated and ranges are displayed in parentheses.